Recent research have centered on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GCGR agonists are increasingly employed for treating type 2 diabetes, their unexpected impacts on reinforcement circuits, specifically mediated by DA systems, are attracting su